Concord Asset Management LLC VA Sells 4,214 Shares of Procter & Gamble Company (The) $PG

Core Viewpoint - Procter & Gamble Company (NYSE: PG) has seen significant changes in institutional holdings, with some investors increasing their stakes while others, like Concord Asset Management, have reduced theirs by 19.4% in the third quarter. The company reported mixed financial results, with a slight year-over-year revenue increase and a dividend announcement. Group 1: Institutional Holdings - Concord Asset Management LLC VA reduced its holdings in Procter & Gamble by 19.4%, owning 17,452 shares worth $2,681,000 after selling 4,214 shares in the third quarter [2] - Other institutional investors have also modified their positions, with Halbert Hargrove Global Advisors LLC buying a new stake valued at approximately $25,000, and Manning & Napier Advisors LLC purchasing shares worth $44,000 [3] - Hedge funds and institutional investors collectively own 65.77% of Procter & Gamble's stock [3] Group 2: Financial Performance - Procter & Gamble reported earnings of $1.88 per share for the last quarter, exceeding analysts' expectations of $1.86 by $0.02, with revenue of $22.21 billion, slightly below the expected $22.36 billion [5] - The company achieved a net margin of 19.30% and a return on equity of 32.21%, with revenue up 1.5% year-over-year [5] - Procter & Gamble has set its FY 2026 EPS guidance at 6.830-7.090, with analysts expecting an EPS of 6.91 for the current fiscal year [5] Group 3: Dividend Information - Procter & Gamble announced a quarterly dividend of $1.0568 per share, to be paid on February 17th, with a record date of January 23rd, representing an annualized dividend of $4.23 and a yield of 2.7% [6] - The company's current payout ratio stands at 62.67% [6] Group 4: Stock Performance and Analyst Ratings - Procter & Gamble shares opened at $159.33, with a 52-week low of $137.62 and a high of $179.99, and a market capitalization of $370.28 billion [4] - Analysts have varied opinions on the stock, with BNP Paribas Exane reducing its target price from $172.00 to $164.00 while maintaining an "outperform" rating [8] - The consensus rating for Procter & Gamble is "Moderate Buy" with a target price of $167.67, with 13 analysts rating it as a Buy and 8 as Hold [8]